Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 4
2005 4
2006 3
2007 6
2008 6
2009 7
2010 6
2011 8
2012 12
2013 7
2014 5
2015 5
2016 6
2017 7
2018 9
2019 11
2020 16
2021 11
Text availability
Article attribute
Article type
Publication date

Search Results

119 results
Results by year
Filters applied: . Clear all
Page 1
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J; CLEOPATRA study group. Swain SM, et al. Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12. Lancet Oncol. 2020. PMID: 32171426 Clinical Trial.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Among authors: ueno t. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.
Breast castleman disease.
Fukuoka M, Ueno T, Yoshida K, Kikuchi M, Takeuchi K, Ohno S. Fukuoka M, et al. Among authors: ueno t. Breast J. 2020 Sep;26(9):1855-1856. doi: 10.1111/tbj.13902. Epub 2020 May 29. Breast J. 2020. PMID: 32469112 No abstract available.
Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021.
Yamamoto M, Yoshida M, Furuse J, Sano K, Ohtsuka M, Yamashita S, Beppu T, Iwashita Y, Wada K, Nakajima TE, Sakamoto K, Hayano K, Mori Y, Asai K, Matsuyama R, Hirashita T, Hibi T, Sakai N, Tabata T, Kawakami H, Takeda H, Mizukami T, Ozaka M, Ueno M, Naito Y, Okano N, Ueno T, Hijioka S, Shikata S, Ukai T, Strasberg S, Sarr MG, Jagannath P, Hwang TL, Han HS, Yoon YS, Wang HJ, Luo SC, Adam R, Gimenez M, Scatton O, Oh DY, Takada T. Yamamoto M, et al. Among authors: ueno t. J Hepatobiliary Pancreat Sci. 2021 Jan;28(1):1-25. doi: 10.1002/jhbp.868. Epub 2020 Dec 12. J Hepatobiliary Pancreat Sci. 2021. PMID: 33200538
[Biomarker].
Ueno T, Toi M. Ueno T, et al. Gan To Kagaku Ryoho. 2009 Jan;36(1):15-20. Gan To Kagaku Ryoho. 2009. PMID: 19151560 Japanese.
Response to Sung, Rosenberg, and Yang.
Lin CH, Yap YS, Lee KH, Yeo W, Ueno T, Li H, Huang SM, Lu YS. Lin CH, et al. Among authors: ueno t. J Natl Cancer Inst. 2020 May 1;112(5):547-548. doi: 10.1093/jnci/djz191. J Natl Cancer Inst. 2020. PMID: 31545369 Free PMC article. No abstract available.
119 results